Approved indication: In the United States, tirofiban is approved to reduce the rate of thrombotic cardiovascular events (death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in adults with non–ST-elevation acute coronary syndrome, usually in combination with aspirin and heparin and often around the time of coronary angiography or percutaneous coronary intervention (PCI).

Off-label uses: Clinicians may use tirofiban off label as an adjunct during PCI in patients with large intracoronary thrombus or no‑reflow, in some ST‑elevation MI cases, or in other high‑thrombus cardiac procedures; evidence comes from randomized trials and observational studies, but practice is selective because of bleeding risk and the availability of potent oral P2Y12 inhibitors.

Efficacy expectations: Platelet inhibition is rapid (within minutes of the bolus), and clinical trials in NSTE‑ACS have shown a modest but meaningful reduction in the composite of death, MI, or refractory ischemia when added to standard therapy, at the cost of increased bleeding. Compared with other glycoprotein IIb/IIIa inhibitors (eptifibatide, abciximab), overall antithrombotic efficacy is similar when appropriately dosed, and use of all agents in this class has shifted toward high‑risk, selectively chosen patients rather than routine use.

Typical adult dosing (NSTE‑ACS): The standard regimen is a 25 mcg/kg intravenous bolus given over up to 5 minutes, immediately followed by a continuous IV infusion of 0.15 mcg/kg/min for up to 18 hours (often around the time of angiography/PCI), together with aspirin and usually unfractionated heparin.

Renal impairment and special dosing: In patients with creatinine clearance ≤60 mL/min, the bolus remains 25 mcg/kg, but the infusion is reduced to 0.075 mcg/kg/min. Dosing is weight‑based and delivered through an infusion pump; no specific adjustment is recommended solely for age, though older adults have higher baseline bleeding risk and require closer observation.

How it is given: Tirofiban is for intravenous use only and is administered by healthcare professionals in monitored settings such as coronary care units or catheterization labs. It is usually started shortly before or during coronary angiography/PCI and is not a medicine patients take at home or with food.

Missed doses and infusion interruptions: Because tirofiban is given as a continuous infusion in the hospital, any interruption, missed bolus, or adjustment is managed by the clinical team, who may re‑calculate dosing and restart the infusion based on the clinical situation.

Overdose management: There is no specific antidote; if too much tirofiban is given, the infusion is stopped, the patient is closely monitored for bleeding, local pressure is applied to access sites, supportive measures (including blood products or platelet transfusion) may be used, and other anticoagulants may be reduced or discontinued as appropriate.

Common side effects: The most frequent problem is bleeding (for example, oozing at catheter or IV sites, nosebleeds, bruising, gum bleeding), usually starting during the infusion; many cases are mild but can be bothersome. Other non‑bleeding effects can include low blood pressure, slow heart rate, dizziness, nausea, or swelling at infusion sites.

Serious or rare adverse effects: Major bleeding (such as gastrointestinal bleeding, retroperitoneal bleeding, or, rarely, intracranial hemorrhage) can be severe or life‑threatening and requires urgent medical attention. Acute, marked thrombocytopenia (a sudden drop in platelets), allergic or anaphylactic reactions, and bleeding requiring transfusion or urgent surgery are uncommon but important risks.

Warnings and precautions: Tirofiban is contraindicated in patients with active internal bleeding, a history of bleeding disorders, recent major surgery or severe trauma (typically within the past month), prior thrombocytopenia caused by tirofiban, or known hypersensitivity to the drug. Dose reduction is required in moderate to severe kidney impairment (creatinine clearance ≤60 mL/min), and use is generally avoided or undertaken with great caution in patients on chronic dialysis. There is limited experience in significant liver disease, so careful monitoring is advised. Safety and effectiveness have not been established in children and adolescents. In pregnancy, animal data are reassuring but human data are lacking, so use is reserved for situations where the potential benefit justifies the risk; breastfeeding is usually avoided during treatment and for a short period afterward because of limited data.

Relative safety versus alternatives: Compared with standard dual antiplatelet therapy alone, adding tirofiban improves antithrombotic effect but increases major and minor bleeding. Its overall safety profile is broadly similar to other GP IIb/IIIa inhibitors, and because it is short‑acting and reversible, bleeding risk generally declines rapidly once the infusion is stopped.

Reporting and safety updates: Side effects can be reported to healthcare professionals and directly to the U.S. Food and Drug Administration’s MedWatch program, and up‑to‑date safety information is available in the prescribing information and on regulatory or manufacturer websites.

Major drug and treatment interactions: Tirofiban’s main interactions are pharmacodynamic, increasing bleeding risk when combined with other agents that affect hemostasis, including anticoagulants (heparin, low‑molecular‑weight heparins, direct oral anticoagulants, warfarin), other antiplatelets (aspirin, clopidogrel, prasugrel, ticagrelor), thrombolytics (such as alteplase), NSAIDs, and some herbal supplements that may promote bleeding (for example, ginkgo, high‑dose fish oil). It is typically used intentionally with aspirin and heparin, but this combination requires careful monitoring. Tirofiban is not known to have significant cytochrome P450–mediated drug–drug interactions.

Food, alcohol, and procedures: There are no specific food interactions because the drug is given intravenously, but heavy alcohol use can further raise bleeding risk. Invasive procedures (arterial and venous punctures, surgery, biopsies) performed while a tirofiban infusion is running have a higher bleeding risk, so clinicians minimize unnecessary punctures and time sheath removal and procedures carefully.

Conditions requiring caution or avoidance: Use is avoided in active bleeding, recent major surgery or major trauma, prior hemorrhagic stroke, uncontrolled severe hypertension, or known bleeding diatheses. Extra caution is required in elderly patients, those with low baseline hemoglobin or platelets, severe renal impairment, or co‑administration of multiple antithrombotic agents.

Monitoring needs: During therapy, patients are typically monitored with frequent checks of platelet count, hemoglobin and hematocrit, clinical assessment for signs of bleeding (including at catheter sites and in stool or urine), blood pressure and heart rate, and renal function. Coagulation tests may be followed mainly to manage concurrent heparin, while ECG and continuous cardiac monitoring are used because patients have acute coronary syndromes rather than for tirofiban itself.

Q: What is tirofiban used for?
A: Tirofiban is an intravenous antiplatelet medicine used in adults with non–ST-elevation acute coronary syndrome to help prevent serious clot‑related events such as heart attack or recurrent ischemia, especially around the time of coronary angiography or angioplasty.

Q: How quickly does tirofiban start working and how long does it stay in my system?
A: Platelet inhibition begins within minutes of the IV bolus, remains while the infusion continues, and largely wears off within several hours after the drug is stopped as new platelets enter the circulation.

Q: Why would my doctor choose tirofiban instead of another antiplatelet drug?
A: Tirofiban provides very strong, rapidly reversible platelet inhibition that can be useful in high‑risk situations such as during PCI with heavy clot burden, and it can be turned off quickly if bleeding occurs, whereas most oral antiplatelet drugs have longer‑lasting effects.

Q: What are the biggest risks while I am receiving tirofiban?
A: The main risk is bleeding, ranging from minor oozing and bruising to, less commonly, serious bleeding that may require transfusion or procedures; rare complications include severe thrombocytopenia and allergic reactions, so staff monitor you closely during the infusion.

Q: Can I receive tirofiban if I have kidney problems?
A: Many patients with kidney impairment can receive tirofiban, but the infusion dose is reduced when creatinine clearance is ≤60 mL/min and the care team monitors for bleeding more closely, while use in dialysis or very advanced kidney failure is considered on a case‑by‑case basis.

Q: Is tirofiban ever continued after I leave the hospital?
A: No, tirofiban is used only as a short‑term, hospital‑based IV infusion; once it is stopped, longer‑term protection is usually provided by oral antiplatelet medicines such as aspirin and a P2Y12 inhibitor.